StemRIM Earnings Beat, Revenue Inline In Q4
- Investing.com
StemRIM, a biotechnology company, develops regeneration medicines for the treatment of intractable diseases. The company develops PJ1, a regeneration induction medicine HMGB1 peptides, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, cerebral infarction, osteoarthritis, and chronic liver disease, as well as cardiomyopathy. Its pre-clinical stage products include PJ2 and PJ3 to treat multiple tissue damage disease; PJ4, an autologous cell sampling device for medical treatment; and PJ5, a stem cell gene therapy. StemRIM was incorporated in 2006 and is based in Ibaraki, Japan.
Metrics to compare | 4599 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship4599PeersSector | |
---|---|---|---|---|
P/E Ratio | −10.4x | −6.6x | −0.5x | |
PEG Ratio | −1.23 | −0.14 | 0.00 | |
Price/Book | 2.6x | 8.3x | 2.6x | |
Price / LTM Sales | - | 50.0x | 3.3x | |
Upside (Analyst Target) | 113.4% | 72.4% | 43.4% | |
Fair Value Upside | Unlock | 8.2% | 7.1% | Unlock |